Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 17/20 | 0.60 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.50 |
| ▸ | PRKDC | P78527 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8193524 | 0.89 | ERN1 (0.76) | ERN1TRIM24TYRTRIM33ALDH1A1 | |
| SCHEMBL7285302 | 0.88 | ERN1 (0.62) | ERN1TRIM24TYRTRIM33ALDH1A1 | |
| SCHEMBL8198276 | 0.85 | ERN1 (0.46) | ERN1TRIM24TYRTRIM33PRKDC | |
| SCHEMBL28610814 | 0.83 | ERN1 (0.50) | ERN1TRIM24TYRTRIM33PRKDC | |
| SCHEMBL28282933 | 0.82 | ERN1 (0.56) | ERN1TRIM24TYRTRIM33ALDH1A1 | |
| SCHEMBL28292328 | 0.82 | ERN1 (0.61) | ERN1TRIM24TYRTRIM33ALDH1A1 | |
| SCHEMBL3645435 | 0.82 | ERN1 (0.61) | ERN1TRIM24TYRTRIM33ALDH1A1 | |
| SCHEMBL13855640 | 0.81 | ERN1 (0.55) | ERN1TRIM24TYRTRIM33ALDH1A1 | |
| SCHEMBL118908 | 0.81 | ERN1 (0.68) | ERN1ALDH1A1 | |
| SCHEMBL6828189 | 0.79 | ERN1 (0.52) | ERN1TRIM24TYRTRIM33PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111943973-A | Bimetallic complex of phenoxy imine ligand skeleton, preparation method and application | 万华化学集团股份有限公司 | 2020-11-17 | — | — | CN | claimed |
| WO-2009009417-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-15 | — | — | WO | claimed |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | WYETH (US) | 2009-01-08 | — | — | US | claimed |
| US-20050038107-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH | 2005-02-17 | — | — | US | claimed |
| EP-1458700-A2 | SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-22 | — | — | EP | claimed |
| US-20030171428-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | WYETH | 2003-09-11 | — | — | US | claimed |
| WO-2003051860-A2 | SUBSTITUTED 2-PHENYL BENZOFURANS AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-26 | — | — | WO | claimed |
| CN-117101726-A | Metal complex catalyst and preparation method of 2, 4-trimethyl adipic acid | 山东新和成维生素有限公司 | 2023-11-24 | — | — | CN | disclosed |
| US-11760773-B2 | Small molecule drug conjugates of gemcitabine monophosphate | MAVERIX ONCOLOGY, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| CN-114761410-B | Pyrrolopyrimidinone compounds and application thereof | 广州必贝特医药股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-111943973-B | Bimetallic complex of phenoxyimine ligand framework, preparation method and application | 万华化学集团股份有限公司 | 2023-06-09 | — | — | CN | disclosed |
| WO-2022213932-A1 | PYRROLOPYRIMIDINONE COMPOUND AND APPLICATION THEREOF | 广州必贝特医药股份有限公司 | 2022-10-13 | — | — | WO | disclosed |
| CN-114761410-A | Pyrrolopyrimidinone compounds and application thereof | 广州必贝特医药股份有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-5290939-A | Process for the manufacture of brofaromine and analogs thereof | CIBA-GEIGY CORPORATION (US) | 1994-03-01 | — | — | US | disclosed |
| EP-0542671-A1 | Substituted hydroquinone derivatives as intermediates of benzofuran derivatives | CIBA-GEIGY AG (CH) | 1993-05-19 | — | — | EP | disclosed |
| EP-0288477-A1 | 2,3-DIHYDRO-1H-PHENALENE-2-AMINO COMPOUNDS AS ANTI-PSYCHOTIC DRUGS | THE UPJOHN COMPANY (US) | 1988-11-02 | — | — | EP | disclosed |
| EP-0234113-A1 | 2,3-Dihydro-1H-phenalene-2-amino compounds as anti-psychotic drugs | THE UPJOHN COMPANY (US) | 1987-09-02 | — | — | EP | disclosed |
| WO-1987004153-A1 | 2,3-DIHYDRO-1H-PHENALENE-2-AMINO COMPOUNDS AS ANTI-PSYCHOTIC DRUGS | THE UPJOHN COMPANY (US) | 1987-07-16 | — | — | WO | disclosed |
| US-4600719-A | Tetrahydropyridine and piperidine derivatives | CIBA GEIGY CORPORATION (US) | 1986-07-15 | — | — | US | disclosed |
| US-4210655-A | Anti-depressant benzofuranyl piperidines | CIBA-GEIGY CORPORATION (US) | 1980-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038107-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | ESR1, ESR2, ESRRA | ERN1 1373/4885TRIM24 3008/4885TYR 2670/4885 |
| US-20090010884-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION | COL2A1, COL1A1, COL14A1 | ERN1 3514/4885TRIM24 3299/4885TYR 363/4885 |
| US-11760773-B2 | Small molecule drug conjugates of gemcitabine monophosphate | ZYX, SLC7A5, GMPS | ERN1 2708/4885TRIM24 3661/4885TYR 2646/4885 |
| US-20030171428-A1 | Substituted 2-phenyl benzofurans as estrogenic agents | ESR1, ESR2, GPER1 | ERN1 1313/4885TRIM24 2982/4885TYR 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.